Funding for this research was provided by:
Cancer Research UK (C16728/A21400)
Bristol-Myers Squibb Foundation (CA209-841)
Text and Data Mining valid from 2018-04-18
Received: 21 December 2017
Accepted: 15 March 2018
First Online: 18 April 2018
Ethics approval and consent to participate
: The trial received favourable ethical opinion from East Midlands – Edgbaston Research Ethics Committee (16/WM/0472) and has Health Research Authority (HRA) approval (IRAS 211270). All participants provide written informed consent to participate and are free to withdraw at any time.
: PS receives honoraria and travel expenses from BMS. SD has received support to attend conferences and speaker fees from BMS. GH has received speaker honoraria from BMS, ROCHE, Merck, AZ and Pfizer. NS has received honoraria for ad boards and speaker fees from BMS. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.